KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Novembro 2023 - 7:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that the compensation committee of KalVista’s board of directors
granted eight newly-hired employees inducement options to purchase
an aggregate of 77,000 shares of KalVista common stock on November
1, 2023 as inducements material to each employee entering into
employment with KalVista. The options were granted in accordance
with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $8.77 per share, which was
equal to the closing price of KalVista common stock on the grant
date. One-fourth of the options vest on the one-year anniversary of
the vesting commencement date and the remainder vest in equal
monthly installments over the next three years, in each case
subject to the new employee’s continued service with the company.
Each stock option has a 10-year term and is subject to the terms
and conditions of KalVista’s Inducement Equity Incentive Plan and a
stock option agreement covering the grant.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company
focused on the discovery, development, and commercialization of
oral, small molecule protease inhibitors for diseases with
significant unmet need. KalVista is developing sebetralstat as an
oral on-demand therapy for HAE attacks and has achieved target
enrollment for the phase 3 KONFIDENT clinical trial. In addition,
KalVista’s oral Factor XIIa inhibitor program represents a new
generation of therapies that may further improve the treatment for
people living with HAE and other diseases.
For more information about KalVista, please visit
www.kalvista.com
For more information on the sebetralstat HAE on-demand Phase 3
KONFIDENT study, please visit www.konfidentstudy.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231103416262/en/
KalVista Pharmaceuticals, Inc.
Jarrod Aldom Vice President, Corporate Communications (201)
705-0254 jarrod.aldom@kalvista.com
Ryan Baker Head, Investor Relations (617) 771-5001
ryan.baker@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024